The WHO's Strategic Advisory Group of Experts on Immunisation (SAGE) updated the plan for prioritising the use of COVID–19 vaccinations to account for Omicron's effects and the strong population-level immunity brought on by infection and immunisation.

The plan maintains SAGE's priority of safeguarding those who are most at risk of passing on SARS-CoV-2 infection and developing and sustaining robust healthcare systems. The COVID-19 immunisation for individuals at lesser risk, especially healthy children and adolescents, is now taken into account by the roadmap when compared to alternative medical interventions. The roadmap now contains updated advice on extra booster dosages and booster intervals. The lowering of post-COVID problems brought on by the current COVID-19 vaccinations is also taken into account, however the data for how much of an influence they have varies.

The high priority group consists of older people, younger people with significant co-morbidities (such as diabetes and heart disease), immunocompromised individuals (such as transplant recipients and people living with HIV), including children aged 6 months and older, pregnant women, and frontline healthcare workers.

Depending on considerations like age and immunocompromising diseases, SAGE advises an extra booster for the high priority category either 6 or 12 months after the last dosage. All COVID-19 vaccination recommendations are temporary and only relate to the current epidemiological situation, thus the extra booster recommendations shouldn't be interpreted as calling for yearly COVID-19 vaccine boosters to continue. Serving nations who are making short- to medium-term plans is the goal.

In order to implement PHSM at various resultant Situational Levels, Member States must first determine the severity of the COVID-19 scenario. This document offers assistance for doing so. The revised advice does away with category transmission categories with numerical cut-offs as a measure for PHSM correction. The COVID-19 morbidity/mortality and health system impact dimensions—both of which were kept from the previous version—become the primary focus of situational evaluation under the guidance. As a result, to reflect these modifications, the situational level matrix and each situational level's language have been revised.

After a second infection, you're less likely than after a first to have lengthy COVID:

Many people who have experienced COVID more than once may be asking whether your likelihood of developing long-lasting COVID symptoms increases or decreases with each subsequent infection.

It seems like the response is no. According to current studies, there is a dramatic decline in the likelihood of lengthy COVID, which includes a range of symptoms such weariness and shortness of breath.